ZUG, Switzerland, July 2, 2015 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced two recent additions to its U.S. intellectual property portfolio. The U.S. Patent and Trademark Office ("USPTO") has issued an Issue Notification for U.S. Patent Application No. 14/448,999, titled "Methods for the Treatment of Tinnitus Induced by Cochlear Excitotoxicity," which will issue as U.S. Patent No. 9,072,662 on July 7, 2015. The patent's key claim is directed to the use of a pharmaceutical composition comprising Ketamine for reducing the perception of tinnitus; it is the third issued U.S. patent covering the use of AM-101 for the treatment of tinnitus.
In addition, the USPTO issued U.S. Patent No. 9,066,865 relating to methods of treating inner or middle ear diseases with intratympanic injections of poloxamer-based compositions. The claims are directed to the use of fluoroquinolone antibiotics in poloxamer 407 compositions under certain specifications. The patent is based on a continuation filing related to U.S. patent application 11/992,632, with priority date of September 28, 2005, which discloses the use of various biocompatible polymers for the controlled release of various active substances for the treatment of diseases of the inner or middle ear.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS".
This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or Auris Medical's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the timing and conduct of clinical trials of Auris Medical's product candidates, the clinical utility of Auris Medical's product candidates, the timing or likelihood of regulatory filings and approvals, Auris Medical's intellectual property position and Auris Medical's financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Auris Medical's capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Auris Medical's prospectus relating to its Registration Statement on Form F-1, as amended, and future filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and Auris Medical does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
Company: Dr. Thomas Meyer, Chairman and CEO, +41 41 729 71 94, email@example.com
Investors: Matthew P. Duffy, Managing Director, LifeSci Advisors, 212-915-0685, firstname.lastname@example.org
Auris Medical Patent Issues http://hugin.info/160190/R/1934062/696328.pdf
Source:Auris Medical AG